Cialis (tadalafil) 2.5 and 5 mg tablets Prior Approval Criteria
Prior authorization policy for pharmacy benefit coverage of Cialis (tadalafil) 2.5 mg and 5 mg tablets, specifying recommended authorization criteria, approved indications, durations, automation rules, documentation requirements, and conditions not recommended for approval. Applies to plans that do not cover Cialis for erectile dysfunction.
No material policy changes — coverage criteria and recommendations remain as previously stated.
Coverage Summary
Cialis (tadalafil) 2.5 mg and 5 mg tablets prior authorization. This policy outlines prior authorization criteria for tadalafil 2.5 mg and 5 mg tablets for non-ED coverage. The primary covered indication is treatment of Benign Prostatic Hyperplasia (BPH) (ICD-10: N40*) and authorization is recommended for those who meet the specified criteria. This prior authorization applies to plans that do not cover Cialis for erectile dysfunction; erectile dysfunction (ED) is excluded from the scope of this prior authorization.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.